NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
NKGen生物技術公司介紹了新型製造和低溫保存的SNK02異體自然殺傷細胞療法；首席執行官Paul Y. Song博士更新了治療晚期難治性實體瘤1期初始結果。
NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors
NKGen生物技術公司介紹了新型製造和低溫保存的SNK02異體自然殺傷細胞療法；首席執行官Paul Y. Song博士更新了治療晚期難治性實體瘤1期初始結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。